

Precipitated Withdrawal Refractory to High-Dose Buprenorphine: A Cautionary Tale

Lisa W. Vercollone, MD, PharmD, Edmond Hakimi, DO, David B. Hathaway, MD, Joji Suzuki, MD

Brigham and Women's/Faulkner Hospitals, Boston, MA Harvard Medical School, Boston, MA (None of the authors have any disclosures to report)




BACKGROUND

In the fentanyl era, traditional approaches to initiating buprenorphine for persons who use non-prescribed opioids on a daily basis carry significant risk of buprenorphine precipitated opioid withdrawal (BPOW). These continued challenges have recently sparked interest in an alternative approach called "macrodosing," or high-dose buprenorphine initiation (HDBI). As its name implies, HDBI entails the administration of large doses of buprenorphine in a short period of time. The intent of using macrodosing/HDBI is to "flood" mu-opioid receptors with buprenorphine in order to rapidly ameliorate opioid withdrawal symptoms. Yet data supporting the safety or effectiveness of macrodosing/HDBI remains limited. Here we present a case where macrodosing/HDBI was employed to treat BPOW occurring after a traditional buprenorphine initiation attempt.

REFERENCES

- 1- Herring AA et al. High-Dose
 Buprenorphine Induction in the Emergency
 Department for Treatment of Opioid Use Disorder.
 JAMA Network Open. 2021 Jul 1;4(7)
- 2 Oakley B et al. Managing opioid withdrawal precipitated by buprenorphine with buprenorphine. Drug Alcohol Rev. 2021;40(4):567-571.
- 3 Quattlebaum THN at al. A case of buprenorphine-precipitated withdrawal managed with high-dose buprenorphine. Fam Pract. 2022;39(2):292-294.
- 4 Huhn AS at al. Protracted renal clearance of fentanyl in persons with opioid use disorder. Drug Alcohol Depend. 2020;214.



DISCUSSION

Case reports suggest that treatment of BPOW with macrodosing/HDBI may ameliorate withdrawal symptoms within 12 hours (1,2). This patient continued to experience severe BPOW 24 hours after macrodosing/HDBI. Many factors were considered.

- Fentanyl is highly lipophilic and has delayed renal clearance leading to the accumulation of high blood levels (4). Given the patient's heavy, chronic fentanyl use, coupled with class II obesity, a significant amount of fentanyl may have persisted despite the fact that over 40 hours had elapsed from last use.
- Concurrent withdrawal syndromes from alcohol, stimulants, and possibly xylazine
- Immediately after buprenorphine is administered at high doses, relatively few opioid-mu receptors remain unoccupied; this may render full mu-opioid receptor agonists with lesser affinity than buprenorphine ineffective and may contribute to severe, persistent BPOW refractory to reversal with full agonist opioids.
- It is also possible that there was a strong contribution of spontaneous opioid (fentanyl) withdrawal, complicated by the patient's poor distress tolerance in the setting of a history of significant life traumas and adverse childhood experiences (ACEs).

Caution is warranted regarding approaches employing high-dose buprenorphine to treat buprenorphine-precipitated opioid withdrawal

RESULTS

A 26-year-old man with multiple substance use disorders including intravenous (IV) fentanyl, stimulants, and tobacco, depressive disorder, PTSD, and class II obesity (BMI 35) admitted for cellulitis.

- Reported a 4-day "binge" of IV fentanyl, methamphetamine, crack cocaine, and alcohol (2 pints vodka daily) with a baseline use of intravenous fentanyl "2 gm" daily for many months.
- Last use of fentanyl was 2 hours prior to presentation. One week prior to this admission, he had received methadone for 3 days in tapering doses of 30 mg, 20 mg, and 10 mg.
- During this admission, he was started on chlordiazepoxide 75 mg PO g6h for alcohol withdrawal syndrome.
- 28 hours after admission, he was found pacing around the room, diaphoretic, anxious, crying, with piloerection and a COWS of 23. Subsequently, he received bup/nal 2 mg/0.5 mg SL x 1 dose.
- 20 minutes later, a repeat COWS was > 36 consistent with severe BPOW.
- Over the next 6 hours, he received a total of bup/nal 24 mg/6 mg SL. COWS improved to a nadir of 15.
- He received an additional bup/nal 8 mg/2 mg SL dose on the initiation day and was placed on TID dosing.
- The following morning, 24 hours after his initial bup/nal dose, his COWS had increased to 25. In response, he received hydromorphone 4 mg IV which he reported made his symptoms worse and he refused additional doses.
- He stated, "I feel like I'm dying. I am very sorry, I need to leave to use and drink and then I will come back," and he left via a self-directed discharge.
- Total: bup/nal 40 mg/10 mg, chlordiazepoxide 375 mg, lorazepam IV 8 mg, hydromorphone IV 4 mg.
- Quantitative urine drug screen collected 40 hours after admission later revealed a urine concentration of fentanyl 62 ng/mL and norfentanyl 399 ng/mL. Urine methadone was detected but not quantified.